Phase 3 Recruiting Network
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it dev…
Sponsor: Children's Oncology Group
NCT ID: NCT03067181
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
+ 563 more sites in the U.S.
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Locations: - Children's Hospital of Alabama — Birmingham, Alabama
- USA Health Strada Patient Care Center — Mobile, Alabama
- Providence Alaska Medical Center — Anchorage, Alaska
+ 200 more sites in the U.S.
Phase 3 Recruiting Academic/Other
This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. I…
Sponsor: Indiana University
NCT ID: NCT06593665
Locations: - Indiana Univeristy — Indianapolis, Indiana
- Indiana University Hospital — Indianapolis, Indiana
Phase 2 Recruiting NIH
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT03866382
Locations: - University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- Anchorage Associates in Radiation Medicine — Anchorage, Alaska
- Anchorage Radiation Therapy Center — Anchorage, Alaska
+ 575 more sites in the U.S.
Phase 2 Recruiting Academic/Other
The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicy…
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06866964
Locations: - Atrium Health Wake Forest Baptist Comprehensive Cancer Center — Charlotte, North Carolina
- Wake Forest Baptist Comprehensive Cancer Center — Winston-Salem, North Carolina
- Aurora St. Luke's Medical Center MOB — Milwaukee, Wisconsin
Phase 2 Recruiting Academic/Other
This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (adv…
Sponsor: Mayo Clinic
NCT ID: NCT05969860
Locations: - Mayo Clinic in Florida — Jacksonville, Florida
- Altru Cancer Center — Grand Forks, North Dakota
Phase 1, Phase 2 Recruiting Academic/Other
Phase I study to examine safety of the addition of concurrent tarlatamab with standard palliative and consolidative RT regimens , with a main cohort of N=20-24 patients with extracranial anatomic radiation sites. I) After lead in of 10 pat…
Sponsor: University of Arizona
NCT ID: NCT06814496
Locations: - Arizona Cancer Center at UMC North/University Medical Center — Tucson, Arizona
- University of Washington Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Academic/Other
The purpose of this study is to assess the safety and effectiveness of a drug called Pedmark® sodium thiosulfate (STS) in reducing hearing impairment with standard of care cisplatin therapy. The safety and effectiveness of STS in reducing …
Sponsor: University of Arizona
NCT ID: NCT07407582
Locations: - University of Arizona Cancer Center — Tucson, Arizona
Phase 2 Recruiting NIH
Background: Many cancers of the testicles and urinary tract are rare diseases; these are diseases that affect less than 200,000 people in the United States. It can be hard to study treatments for these diseases. One combination of drugs-en…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06041503
Locations: - National Institutes of Health Clinical Center — Bethesda, Maryland
Phase 1 Recruiting Industry
The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tu…
Sponsor: Xencor, Inc.
NCT ID: NCT06276491
Locations: - City of Hope — Duarte, California
- Stanford — Palo Alto, California
- University of California — San Francisco, California
+ 13 more sites in the U.S.
Phase 1 Recruiting Industry
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody, in participants with platinum-refractory/resistant ov…
Sponsor: Context Therapeutics Inc.
NCT ID: NCT06515613
Locations: - University of Arkansas Winthrop P. Rockefeller Cancer Institute — Little Rock, Arkansas
- Precision NextGen Oncology & Research Center — Beverly Hills, California
- SCRI at Denver Health — Denver, Colorado
+ 10 more sites in the U.S.
Phase 1 Recruiting Academic/Other
This phase I trial evaluates whether adding Pedmark to standard of care cisplatin-based chemotherapy reduces drug-induced ear damage (ototoxicity) in men with stage II-III testicular germ cell tumors that have spread from where they first …
Sponsor: City of Hope Medical Center
NCT ID: NCT07218913
Locations: - City of Hope Medical Center — Duarte, California